Publication number: 20090325928
Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
Type:
Application
Filed:
August 12, 2009
Publication date:
December 31, 2009
Inventors:
Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
Publication number: 20090197862
Abstract: 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Type:
Application
Filed:
February 4, 2009
Publication date:
August 6, 2009
Inventors:
Arno G. Steinig, Mark J. Mulvihill, Jing Wang, Douglas S. Werner, Qinghua Weng, Julie Kan, Heather Coate, Xin Chen
Publication number: 20090118499
Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
Type:
Application
Filed:
October 3, 2008
Publication date:
May 7, 2009
Inventors:
Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
Publication number: 20060235031
Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
Type:
Application
Filed:
March 31, 2005
Publication date:
October 19, 2006
Inventors:
Lee Arnold, Heather Coate, Andrew Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Mark Mulvihill, Anthony Nigro, Bijoy Panicker, Arno Steinig, Qingua Weng, Douglas Werner, Michael Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun